Target Organ Damage in African American Hypertension: Role of APOL1

[1]  C. Langefeld,et al.  Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Rocco,et al.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  T. Srinivas.  Defining Living Kidney Donor ESRD Risk—Looking Beyond Race and Gender , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  A. Howie.  Problems with 'focal segmental glomerulosclerosis' , 2011, Pediatric Nephrology.

[5]  C. Young,et al.  Ethnic and Gender Related Differences in the Risk of End‐Stage Renal Disease After Living Kidney Donation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Köttgen,et al.  The MYH9/APOL1 region and chronic kidney disease in European-Americans. , 2011, Human molecular genetics.

[7]  Nicholette D. Palmer,et al.  Differential Effects of MYH9 and APOL1 Risk Variants on FRMD3 Association with Diabetic ESRD in African Americans , 2011, PLoS genetics.

[8]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  A. Köttgen,et al.  Race differences in access to health care and disparities in incident chronic kidney disease in the US. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Jasmin Divers,et al.  A genome-wide association study for diabetic nephropathy genes in African Americans. , 2011, Kidney international.

[11]  M. Rocco,et al.  Coincident idiopathic focal segmental glomerulosclerosis collapsing variant and diabetic nephropathy in an African American homozygous for MYH9 risk variants. , 2011, Human pathology.

[12]  Scott M. Gordon,et al.  High density lipoprotein: it's not just about lipid transport anymore , 2011, Trends in Endocrinology & Metabolism.

[13]  Mathew Cooper,et al.  The state of U.S. living kidney donors. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[14]  Keith C. Norris,et al.  Intensive blood-pressure control in hypertensive chronic kidney disease. , 2010, The New England journal of medicine.

[15]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[16]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[17]  C. Winkler,et al.  Worldwide Distribution of the MYH9 Kidney Disease Susceptibility Alleles and Haplotypes: Evidence of Historical Selection in Africa , 2010, PloS one.

[18]  C. Winkler,et al.  MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing? , 2010, Seminars in nephrology.

[19]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[20]  C. Winkler,et al.  The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans , 2010, American Journal of Nephrology.

[21]  B. Freedman,et al.  The spectrum of MYH9-associated nephropathy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[22]  G. Howard,et al.  Poverty and Racial Disparities in Kidney Disease: The REGARDS Study , 2010, American Journal of Nephrology.

[23]  C. Langefeld,et al.  Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  R. Steiner.  ‘Normal for Now’ or ‘At Future Risk’: A Double Standard for Selecting Young and Older Living Kidney Donors , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  C. Winkler,et al.  Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15 , 2010, Human molecular genetics.

[26]  T. Oyetunji,et al.  Effect of donor ethnicity on kidney survival in different recipient pairs: an analysis of the OPTN/UNOS database. , 2009, Transplantation proceedings.

[27]  C. Winkler,et al.  Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  B. Vanhollebeke,et al.  Human innate immunity against African trypanosomes. , 2009, Current opinion in immunology.

[29]  Thomas Meitinger,et al.  Genome-wide linkage analysis of serum creatinine in three isolated European populations. , 2009, Kidney international.

[30]  C. Davis.  Living kidney donors: current state of affairs. , 2009, Advances in chronic kidney disease.

[31]  Yongmei Liu,et al.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. , 2009, Kidney international.

[32]  Stephen S. Rich,et al.  Genome-Wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes , 2009, Diabetes.

[33]  M. Leppert,et al.  Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene (MYH9) Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study , 2009, American Journal of Nephrology.

[34]  B. Freedman,et al.  Hypertension-associated kidney disease: perhaps no more. , 2008, Journal of the American Society of Nephrology : JASN.

[35]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[36]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[37]  Zhihe Liu,et al.  Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death* , 2008, Journal of Biological Chemistry.

[38]  B. Kestenbaum,et al.  Differences in Kidney Function and Incident Hypertension: The Multi-Ethnic Study of Atherosclerosis , 2008, Annals of Internal Medicine.

[39]  Douglas W. Smith,et al.  Chromogranin A polymorphisms are associated with hypertensive renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[40]  L. Kuller,et al.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.

[41]  A. Monaco,et al.  Preemptive Plasmapheresis and Recurrence of FSGS in High‐Risk Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  B. Freedman,et al.  Population-Based Screening for Family History of End-Stage Renal Disease among Incident Dialysis Patients , 2005, American Journal of Nephrology.

[43]  D. Bowden,et al.  Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. , 2005, Kidney international.

[44]  K. Johansen,et al.  Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. , 2004, Journal of the American Society of Nephrology : JASN.

[45]  Scott M. Williams,et al.  A high-density admixture map for disease gene discovery in african americans. , 2004, American journal of human genetics.

[46]  Keith C. Norris,et al.  The rationale and design of the AASK cohort study. , 2003, Journal of the American Society of Nephrology : JASN.

[47]  B. Freedman.  Susceptibility genes for hypertension and renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[48]  R. Cooper,et al.  Race and genomics. , 2003, The New England journal of medicine.

[49]  R. Brasseur,et al.  Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.

[50]  S. Korbet.  Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. , 2003, Seminars in nephrology.

[51]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[52]  C. Marcantoni,et al.  Hypertensive nephrosclerosis in African Americans versus Caucasians. , 2002, Kidney international.

[53]  B. Kiberd,et al.  Cumulative risk for developing end-stage renal disease in the US population. , 2002, Journal of the American Society of Nephrology : JASN.

[54]  B. Freedman.  End-stage renal failure in African Americans: insights in kidney disease susceptibility. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  A. Kirk,et al.  Effect of Donor Factors on Early Graft Survival in Adult Cadaveric Renal Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[56]  G. Ghiggeri,et al.  Inhibition of renal permeability towards albumin: A new function of apolipoproteins with possible pathogenetic relevance in focal glomerulosclerosis , 2001, Electrophoresis.

[57]  S. Iyengar,et al.  Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  F. Port,et al.  Effect of waiting time on renal transplant outcome. , 2000, Kidney international.

[59]  V. Savin,et al.  "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. , 1999, Journal of the American Society of Nephrology : JASN.

[60]  B. Freedman,et al.  Family history of end-stage renal disease among incident dialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[61]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[62]  B. Freedman,et al.  Familial risk, age at onset, and cause of end-stage renal disease in white Americans. , 1995, Journal of the American Society of Nephrology : JASN.

[63]  B. Freedman,et al.  The link between hypertension and nephrosclerosis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[64]  J. Curtis,et al.  Clinical documentation of end-stage renal disease due to hypertension. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[65]  B. Freedman.  Renal microvascular susceptibility in African American pedigrees. , 1993, Transplantation proceedings.

[66]  B. Freedman,et al.  The familial risk of end-stage renal disease in African Americans. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  R. Neuwirth,et al.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.

[68]  M. Blaufox,et al.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.

[69]  N. Schork,et al.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[70]  C. Langefeld,et al.  Genetic admixture: a tool to identify diabetic nephropathy genes in African Americans. , 2008, Ethnicity & disease.

[71]  G. Ghiggeri,et al.  Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. , 2001, Journal of the American Society of Nephrology : JASN.

[72]  J. Breyer,et al.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.

[73]  P. Whelton,et al.  Diagnosis of hypertensive end-stage renal disease: effect of patient's race. , 1995, American journal of epidemiology.